Patents Examined by Paul W Dickinson
  • Patent number: 12064492
    Abstract: The present invention refers to cells from a subpopulation of progenitors of endothelial cells loaded with gold nanoparticles sensitive to excitation with infrared radiation with consequent release of thermal energy, to a composition having a plurality of these cells and to their use in the diagnosis and treatment of solid tumours thanks to the selective localization of the composition in the tumour mass, which can be thus identified easily for diagnostic purposes by marking the cells with appropriate marking agents, or treated by stimulation with pulsed laser beam up to the complete cauterization of the tumour mass for a targeted and highly effective therapeutic action.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: August 20, 2024
    Assignee: Universita degli Studi di Firenze
    Inventors: Angela Zoppi, Mario Del Rosso, Anna Laurenzana, Gabriella Fibbi, Francesca Margheri, Anastasia Chilla', Giancarlo Margheri
  • Patent number: 12042544
    Abstract: Provided are a stem cell-nano anticancer drug complex in which an anticancer drug based on carbon nanotubes (CNT) and gold (Au) nano particles is loaded on the surface of stem cells, which can overcome side effects of conventional stem cells and targeting limitations of nano anticancer drugs and whose anticancer effect is very excellent, the use thereof, and a method for preparing the same.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: July 23, 2024
    Assignee: GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Dong Woo Khang, Yeon Kyung Lee, Sang-Woo Kim, Jun-Young Park
  • Patent number: 12016931
    Abstract: The present invention provides nanoparticles comprising: (a) an amphiphilic polymer with a number average molecular weight (Mn) of 20,000 g/mol or less; and (b) a peptide that is covalently linked to the polymer, wherein the peptide comprises 8 to 50 amino acids, including an N-terminal linker sequence comprising at least one Arg amino acid residue and a sequence comprising an MHC binding sequence comprising a T cell receptor epitope. The present invention further comprises compositions comprising respective nanoparticles and a liquid or lyophilized carrier as well as nanoparticles and compositions of the invention for use in inducing tolerance to a therapeutic compound (protein, viral vector, lipid vesicle), an allergen or to an autoantigen or for treating an allergy, an autoimmune disease, an exogenous antigen (transplantation antigens, drugs) or a food intolerance.
    Type: Grant
    Filed: July 26, 2023
    Date of Patent: June 25, 2024
    Assignee: Topas Therapeutics GmbH
    Inventors: Johannes Pohlner, Reinaldo Digigow, Barbara Metzler, Sabine Fleischer
  • Patent number: 12005129
    Abstract: In one aspect, compositions are described herein. In some embodiments, a composition described herein comprises, consists of, or consists essentially of an MRI-active or MRI-sensitive polymer or oligomer formed from (i) a non-alkoxylated and non-alkenoxylated citric acid, citrate, or ester/amide of citric acid, and optionally an alkoxylated or alkenoxylated citric acid, citrate, or ester/amide of citric acid, (ii) a polyol/polyamine such as a diol/diamine, (iii) a monomer comprising an MRI contrast agent, and (iv) an amino acid monomer. The polymer or oligomer may be photoluminescent and MRI-sensitive. In another aspect, imaging methods utilizing the compositions described herein are described. In another aspect, scaffolds, grafts, and films comprising, consisting of, or consisting essentially of the compositions described herein are described.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: June 11, 2024
    Assignee: THE PENN STATE RESEARCH FOUNDATION
    Inventors: Jian Yang, Dingying Shan, Nanyin Zhang
  • Patent number: 11992506
    Abstract: Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic islet cells. In some aspects, the methods provided herein relate to generation of pancreatic ? cell, ? cell, ? cells, and EC cells in vitro. In some aspects, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.
    Type: Grant
    Filed: November 1, 2022
    Date of Patent: May 28, 2024
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: George Harb, Chunhui Xie, Bryce W. Carey, Aleksander Szymaniak, Christopher Thanos, Evrett Thompson, Rebecca Chinn, Suyash Raj
  • Patent number: 11963605
    Abstract: The present disclosure relates to, inter alia, a green technology for crosslinking protein molecules for various uses, where the protein molecules can be contained in protein fibers such as, but not limited to, human hair, animal fibers, and mixtures thereof. In one aspect, the present disclosure relates to a crosslinking agent comprising an oxidized sugar having at least two aldehyde groups. In another aspect, the present disclosure relates to a method of crosslinking protein fibers. This method involves providing the aforementioned crosslinking agent and infiltrating a plurality of non-crosslinked protein fibers with the crosslinking agent under conditions effective to cause protein molecules contained in the non-crosslinked protein fibers to become crosslinked, thereby yielding a population of crosslinked protein fibers.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: April 23, 2024
    Assignee: CORNELL UNIVERSITY
    Inventors: Anil N. Netravali, Yidong Zhong
  • Patent number: 11957760
    Abstract: The disclosure relates to nanoparticle drug conjugates (NDC) that comprise ultrasmall nanoparticles, folate receptor (FR) targeting ligands, and linker-drug conjugates, and methods of making and using them to treat cancer.
    Type: Grant
    Filed: March 14, 2023
    Date of Patent: April 16, 2024
    Assignee: Elucida Oncology, Inc.
    Inventors: Kai Ma, Aranapakam M. Venkatesan, Feng Chen, Fei Wu, Melik Ziya Türker, Thomas Courtney Gardinier, II, Geno J. Germano, Jr., Gregory Paul Adams, Francis Y. F. Lee
  • Patent number: 11950995
    Abstract: A bioartificial device, such as a bioartificial pancreas, for implantation in a patient's vascular system. The bioartificial pancreas includes a scaffold adapted to engage an interior wall of a blood vessel, a cellular complex support by the scaffold and extending longitudinally within the interior cavity of the scaffold so as to be exposed to the blood flow when the scaffold is engaged with the blood vessel, the cellular complex support comprising one or more pockets bordered by thin film; and cellular complex comprising pancreatic islets disposed in the one or more pockets, the thin film being adapted to permit oxygen and glucose to diffuse from flowing blood into the one or more pockets at a rate sufficient to support the viability of the islets. The invention also includes methods of making and using a bioartificial pancreas.
    Type: Grant
    Filed: March 31, 2023
    Date of Patent: April 9, 2024
    Assignee: ISLA Technologies, Inc.
    Inventors: Sara Joan Photiadis, Douglas Marc Photiadis, Thomas A. Kramer
  • Patent number: 11945789
    Abstract: Disclosed are XBP-1/IRE-1 inhibitors having formula disclosed herein. Methods of making and using these inhibitors for the treatment of cancer, in particular B cell cancers, are also disclosed. Also disclosed is a genetic XBP-1-knockout cancer mouse model.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: April 2, 2024
    Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
    Inventors: Juan R. Del Valle, Chih-Chi Andrew Hu
  • Patent number: 11925692
    Abstract: The present invention pertains to the field of pre-functionalized nanoparticles (NPs). It relates more particularly to NPs pre-functionalized using a self-assembled monolayer (SAM) and also to NPs functionalized using biomolecules such that the NPs are stable in solution. These NPs may be used in numerous applications, especially as a diagnostic tool, for depleting a molecule of interest in a solution, and therapeutic tool.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: March 12, 2024
    Assignees: Ecole Normale Supérieure Paris-Saclay, Centre National de la Recherche Scientifique
    Inventors: Claude Nogues, Malcolm Buckle, Stéphanie Vial
  • Patent number: 11918657
    Abstract: Low-generation dendrimers containing a high density of surface hydroxyl groups, and methods of synthesis thereof are provided. In particular, oligo ethylene glycol (OEG)-like dendrimers with a high surface functional groups at relatively low generations (e.g. ˜120 hydroxyls in the third generation, with a size of just 1-2 nm) is described. Dendrimer formulations including one or more prophylactic, therapeutic, and/or diagnostic agents, and methods of use thereof are also described. The formulations are suitable for topical, enteral, and/or parenteral delivery for treating one or more diseases, conditions, and injuries in the eye, the brain and nervous system (CNS), particularly those associated with pathological activation of microglia and astrocytes.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: March 5, 2024
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Kannan Rangaramanujam, Rishi Sharma, Anjali Sharma, Sujatha Kannan, Zhi Zhang, Siva Pramodh Kambhampati
  • Patent number: 11896599
    Abstract: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: February 13, 2024
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Padmanabh P. Bhatt, Argaw Kidane, Kevin Edwards
  • Patent number: 11896800
    Abstract: Disclosed herein are self-degradable microneedle devices for the controlled-release of an immunotherapeutic agent. Also disclosed are methods for treating a disease (for example, cancer) using a self-degradable microneedle patch for the sustained delivery of an immunotherapeutic agent (for example, a PD1 antibody).
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: February 13, 2024
    Assignee: NORTH CAROLINA STATE UNIVERSITY
    Inventors: Zhen Gu, Chao Wang, Yanqi Ye
  • Patent number: 11865193
    Abstract: Silica nanocarriers hybridized with superparamagnetic iron oxide nanoparticles (“SPIONs”) and curcumin through equilibrium or enforced adsorption technique. Methods for dual delivery of SPIONs and curcumin to a target for diagnosis or therapy, for example, for SPION-based magnetic resonance imaging or for targeted delivery of curcumin to a cell or tissue. The technique can be extend to co-precipitation of mixed metal oxide involving Ni, Mn, Co and Cu oxide. The calcination temperature can be varied from 500-900° C. The nanocombination is functionalized with chitosan, polyacrylic acid, PLGA or another agent to increase its biocompatibility in vivo.
    Type: Grant
    Filed: August 16, 2023
    Date of Patent: January 9, 2024
    Assignee: Imam Abdulrahman Bin Faisal University
    Inventors: B. Rabindran Jermy, Vijaya Ravinayagam
  • Patent number: 11828006
    Abstract: Resorbable multifilament yarns and monofilament fibers including poly-4-hydroxybutyrate and copolymers thereof with high tenacity or high tensile strength have been developed. The yarns and fibers are produced by cold drawing the multifilament yarns and monofilament fibers before hot drawing the yarns and fibers under tension at temperatures above the melt temperature of the polymer or copolymer. These yarns and fibers have prolonged strength retention in vivo making them suitable for soft tissue repairs where high strength and strength retention is required. The multifilament yarns have tenacities higher than 8.1 grams per denier, and in vivo, retain at least 65% of their initial strength at 2 weeks. The monofilament fibers retain at least 50% of their initial strength at 4 weeks in vivo. The monofilament fibers have tensile strengths higher than 500 MPa. These yarns and fibers may be used to make various medical devices for various applications.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: November 28, 2023
    Assignee: Tepha, Inc.
    Inventors: Amit Ganatra, Fabio Felix, Bhavin Shah, Matthew Bernasconi, Said Rizk, David P. Martin, Simon F. Williams
  • Patent number: 11813375
    Abstract: A novel therapeutic agent for solid cancer capable of hardening the cellular tissue itself of a solid cancer to induce death or growth inhibition of cancer cells, causing solidification of the tissue, is disclosed. The therapeutic agent for solid cancer is composed of a liquid composition containing as an active component an ethoxy-containing compound capable of undergoing polycondensation in a cellular tissue. The therapeutic agent for solid cancer is capable of hardening the cellular tissue itself of a solid cancer such as lung cancer to induce death or growth inhibition of cancer cells, causing solidification of the tissue. In conventional therapeutic methods, the risk of metastasis due to spreading of cancer cells through the bloodstream cannot be eliminated. In contrast, this therapeutic agent for solid cancer instantly surrounds cancer cells, so that the risk of metastasis can be largely reduced.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: November 14, 2023
    Assignee: YANCHERS INC.
    Inventor: Junichi Shimada
  • Patent number: 11806355
    Abstract: The invention relates to compositions containing water-soluble poly(oxazoline) and organic polymer particles chosen from the group of polyolefins, polyvinyl aromatics, polyvinyl esters, polyesters, polyamides, polyimides, polycarboxylic acids, polycarboxilic acid esters, polycarboxylic acid amides, polynitriles, polysulfonic acids, polyketones, polysulfones, polymeric polyols, polyurethanes, proteins, polymeric carbohydrates, nucleic acids or from a mixture of two or more of these polymers. The water-soluble poly(oxazolin) acts as a stabilizer for the polymer particles and can particularly advantageously be used as a stabilizer in the freeze-drying of aqueous polymer dispersions.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: November 7, 2023
    Assignee: Friedrich-Schiller-Universitaet Jena
    Inventors: Meike Nicole Leiske, Anja Traeger, Ulrich Sigmar Schubert
  • Patent number: 11793892
    Abstract: Silica nanocarriers hybridized with superparamagnetic iron oxide nanoparticles (“SPIONs”) and curcumin through equilibrium or enforced adsorption technique. Methods for dual delivery of SPIONs and curcumin to a target for diagnosis or therapy, for example, for SPION-based magnetic resonance imaging or for targeted delivery of curcumin to a cell or tissue. The technique can be extend to co-precipitation of mixed metal oxide involving Ni, Mn, Co and Cu oxide. The calcination temperature can be varied from 500-900° C. The nanocombination is functionalized with chitosan, polyacrylic acid, PLGA or another agent to increase its biocompatibility in vivo.
    Type: Grant
    Filed: June 16, 2021
    Date of Patent: October 24, 2023
    Assignee: Imam Abdulrahman Bin Faisal University
    Inventors: B. Rabindran Jermy, Vijaya Ravinayagam
  • Patent number: 11779664
    Abstract: A liposomal composition (“ADx-003”) is provided, ADx-003 comprising a first phospholipid; a sterically bulky excipient that is capable of stabilizing the liposomal composition; a second phospholipid that is derivatized with a first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid that is derivatized with a second polymer, the second polymer being conjugated to a targeting ligand, the targeting ligand being represented by Formula I: wherein X is —CH2—, —CH2—CH2—, —CHO—, or —O—CO—; Y is —CH—CH?CH— or A and B are independently selected from C and N; R1, R2, R3, and R4 are independently selected from —H, halogen, —OH, and —CH3; and R5, R6, and R7 are independently selected from —H, halogen, —OH, —OCH3, —NO2, —N(CH3)2, C1-C6 alkyl, or a substituted or unsubstituted C4-C6 aryl group, except that when A and/or B is N the adjacent R5 and/or R7 is —H, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 5, 2022
    Date of Patent: October 10, 2023
    Assignees: Texas Children's Hospital, Alzeca Biosciences, LLC
    Inventors: Eric A. Tanifum, Xianwei Sun, Ananth V. Annapragada, Carlo Medici
  • Patent number: 11744897
    Abstract: The disclosure relates to nanoparticle drug conjugates (NDC) that comprise ultrasmall nanoparticles, folate receptor (FR) targeting ligands, and linker-drug conjugates, and methods of making and using them to treat cancer.
    Type: Grant
    Filed: July 18, 2022
    Date of Patent: September 5, 2023
    Assignee: Elucida Oncology, Inc.
    Inventors: Kai Ma, Aranapakam M. Venkatesan, Feng Chen, Fei Wu, Melik Ziya Türker, Thomas Courtney Gardinier, II, Geno J. Germano, Jr., Gregory Paul Adams, Francis Y. F. Lee